NuCana BioMed
NuCana BioMed is a clinical-stage biopharmaceutical company developing rationally designed anti-cancer nucleoside analogues using its proprietary ProTide delivery platform, targeting patients with treatment-resistant cancers.
- Company typePublic
- Founded1997
- HeadquartersEdinburgh, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What NuCana BioMed does
NuCana BioMed (legal entity: NuCana plc) is a clinical-stage biopharmaceutical company headquartered in Edinburgh, United Kingdom, publicly traded on NASDAQ under the ticker NCNA. The company develops rationally designed nucleoside analogue anti-cancer medicines intended to overcome cancer cell resistance mechanisms. Its technology foundation is the proprietary ProTide platform, a nucleotide analogue delivery architecture engineered to enable nucleoside analogues to enter cancer cells more efficiently and bypass common resistance pathways. The active pipeline consists of two lead candidates, NUC-7738 and NUC-3373, both in clinical development with planned strategic milestones through 2026 and promising clinical signals reported in Q3 2025. The target population is patients with treatment-resistant or refractory cancers.
NuCana BioMed firmographics
Firmographics- Name
- NuCana BioMed
- Legal name
- NuCana plc
- Website
- https://nucanabiomed.com
- Company type
- Public
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- NuCana BioMed is a clinical-stage biopharmaceutical company developing rationally designed anti-cancer nucleoside analogues using its proprietary ProTide delivery platform, targeting patients with treatment-resistant cancers.
- Ownership category
- akta.pro rank
NuCana BioMed industry classification
Industry- Product category
- Oncology Pharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)
Keywords
Where NuCana BioMed is headquartered
LocationHeadquarters
- HQ city
- Edinburgh
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
NuCana BioMed business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
NuCana BioMed product offering
Product offeringCore offering
NuCana BioMed is a clinical-stage biopharmaceutical company developing rationally designed anti-cancer medicines using its proprietary ProTide nucleotide analogue delivery platform. Its pipeline centers on two drug candidates, NUC-7738 and NUC-3373, which are nucleoside analogues engineered to bypass cancer cell resistance mechanisms and improve efficacy over conventional chemotherapy.
Product overview
NuCana BioMed is a clinical-stage biopharmaceutical company developing a focused portfolio of anti-cancer medicines. The company's pipeline consists of two lead drug candidates, NUC-7738 and NUC-3373, both in active clinical development with promising data supporting their therapeutic potential. The company operates as a single-product-focus organization advancing these distinct cancer treatments through clinical trials.
Differentiator
Problem solved
Functional benefit
Brands
- NUC-7738: Anti-cancer medicine in clinical development
- NUC-3373
Products and services
- NUC-7738 NUC-7738 is an anti-cancer medicine in clinical development, designed as a nucleoside analogue to overcome cancer cell resistance mechanisms. It is intended for oncology patients with treatment-resistant or refractory cancers.
- NUC-3373 NUC-3373 is an anti-cancer medicine in clinical development targeting cancer cell resistance pathways. It is intended as a next-generation chemotherapy agent for oncology patients with limited treatment alternatives.
Quantifiable outcome
- Promising data supporting the potential of NUC-7738 and NUC-3373 anti-cancer medicines with new clinical signals
Companies that use NuCana BioMed
Customer profileSegments1 record
Ideal customer profiles1 record
NuCana BioMed technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
NuCana BioMed partnerships and signals
Strategic signalScale indicators3 records
Recent moves4 records
Expansion highlights4 records
NuCana BioMed competitors and assessment
Company assessmentBroad incumbents
- Gilead Sciences: Gilead owns sofosbuvir (Sovaldi/Harvoni), the landmark ProTide-based antiviral acquired through the Pharmasset acquisition. As the established commercial leader in ProTide-derived drugs, Gilead is a relevant incumbent comparable for understanding platform validation, regulatory pathway, and market dynamics for ProTide-enabled therapeutics.
- Daiichi Sankyo: Daiichi Sankyo is a Japanese pharmaceutical company with significant oncology focus, including the Enhertu ADC platform developed with AstraZeneca. It is a relevant incumbent comparable as a major oncology player that has successfully commercialized platform-derived oncology assets.
- Roche: Roche is one of the largest oncology pharmaceutical companies globally with deep clinical development capabilities across small molecules, biologics, and ADCs. It is a relevant incumbent comparable for understanding competitive dynamics and potential acquirer profiles in oncology drug development.
- Merck & Co. Merck is a major oncology pharmaceutical company with Keytruda as its flagship asset and active development in small-molecule and combination oncology therapies. It is a relevant incumbent comparable for understanding the competitive landscape and platform validation dynamics in oncology.
- Bristol-Myers Squibb: Bristol-Myers Squibb is a major oncology pharmaceutical company with significant investment in small-molecule and immuno-oncology therapeutics. It is a relevant incumbent comparable for understanding partnership dynamics and competitive positioning in oncology clinical development.
- Pfizer: Pfizer is one of the largest pharmaceutical companies globally with substantial oncology operations across small molecules, biologics, and ADCs. It is a relevant incumbent comparable for understanding the competitive landscape and as a representative potential acquirer in oncology drug development.
Direct peers
- Atea Pharmaceuticals: Atea Pharmaceuticals develops antivirals using ProTide technology, the same nucleotide analogue delivery platform employed by NuCana. This makes Atea the most directly comparable peer in terms of underlying technology approach, though Atea focuses on antiviral indications rather than oncology.
Emerging players
- Bicycle Therapeutics: Bicycle Therapeutics is a UK-based clinical-stage biotech developing bicyclic peptide drug conjugates for oncology. It is comparable to NuCana as a similarly-sized UK-headquartered clinical-stage oncology company with a proprietary technology platform targeting cancer indications.
- Antengene: Antengene is a clinical-stage oncology biotech with operations across Asia-Pacific and a pipeline spanning hematology and solid tumors. It is comparable to NuCana as a similarly-sized clinical-stage oncology company developing novel therapeutics, though Antengene operates primarily in different geographies.
Regional players
- Redx Pharma: Redx Pharma is a UK-based clinical-stage biotech developing small-molecule therapeutics for oncology and fibrotic diseases. It is comparable to NuCana as a similarly-sized UK-headquartered clinical-stage company focused on small-molecule cancer drug development with similar resourcing profiles.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat2 records
Key risks6 records
Key highlights6 records
Customer concentration
NuCana BioMed social profiles
Digital presenceNuCana BioMed financial estimates
Financial estimateRevenue estimate
Valuation estimate
NuCana BioMed leadership team
Management profileNumber of profiles
Profiles6 records
NuCana BioMed funding detail
Funding detailFunding overview
Funding rounds6 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NuCana BioMed M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NuCana BioMed
What does NuCana BioMed do?
NuCana BioMed is a clinical-stage biopharmaceutical company developing rationally designed anti-cancer medicines using its proprietary ProTide nucleotide analogue delivery platform. Its pipeline centers on two drug candidates, NUC-7738 and NUC-3373, which are nucleoside analogues engineered to bypass cancer cell resistance mechanisms and improve efficacy over conventional chemotherapy.
Is NuCana BioMed a public or private company?
NuCana BioMed is a public company. It is classified as public and is currently operating.
When was NuCana BioMed founded?
NuCana BioMed was founded in 1997. It employs 11 to 50 people.
Where is NuCana BioMed based?
NuCana BioMed is headquartered in Edinburgh, United Kingdom, in the Europe region.
Who are NuCana BioMed's main competitors?
Broad incumbents on record are Gilead Sciences, Daiichi Sankyo, Roche, Merck & Co., Bristol-Myers Squibb and Pfizer. Atea Pharmaceuticals is listed as a direct peer. Emerging players are Bicycle Therapeutics and Antengene. Redx Pharma is listed as a regional player.
Does NuCana BioMed have an API?
No public API is recorded for NuCana BioMed.
What industry is NuCana BioMed in?
NuCana BioMed's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support. Its NAICS code is 541714 and its SIC code is 2834.